Next Article in Journal
Interplay between P-Glycoprotein Expression and Resistance to Endoplasmic Reticulum Stressors
Next Article in Special Issue
Melatonin Alleviates High Temperature-Induced Pollen Abortion in Solanum lycopersicum
Previous Article in Journal
Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy
Previous Article in Special Issue
Pineal Calcification, Melatonin Production, Aging, Associated Health Consequences and Rejuvenation of the Pineal Gland
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Molecules 2018, 23(2), 336; https://doi.org/10.3390/molecules23020336

Melatonin: A Molecule for Reducing Breast Cancer Risk

Department of Physiology and Pharmacology, School of Medicina, University of Cantabria, 39011 Santander, Spain
*
Author to whom correspondence should be addressed.
Received: 9 January 2018 / Revised: 31 January 2018 / Accepted: 31 January 2018 / Published: 6 February 2018
View Full-Text   |   Download PDF [2217 KB, uploaded 6 February 2018]   |  

Abstract

The objective of this article is to review the basis supporting the usefulness of melatonin as an adjuvant therapy for breast cancer (BC) prevention in several groups of individuals at high risk for this disease. Melatonin, as a result of its antiestrogenic and antioxidant properties, as well as its ability to improve the efficacy and reduce the side effects of conventional antiestrogens, could safely be associated with the antiestrogenic drugs presently in use. In individuals at risk of BC due to night shift work, the light-induced inhibition of melatonin secretion, with the consequent loss of its antiestrogenic effects, would be countered by administering this neurohormone. BC risk from exposure to metalloestrogens, such as cadmium, could be treated with melatonin supplements to individuals at risk of BC due to exposure to this xenoestrogen. The BC risk related to obesity may be reduced by melatonin which decrease body fat mass, inhibits the enhanced aromatase expression in obese women, increases adiponectin secretion, counteracts the oncogenic effects of elevated concentrations of leptin; and decreases blood glucose levels and insulin resistance. Despite compelling experimental evidence of melatonin’s oncostatic actions being susceptible to lowering BC risk, there is still a paucity of clinical trials focused on this subject. View Full-Text
Keywords: melatonin; breast cancer risk; antiestrogens; light-at-night; shift work; metalloestrogens; cadmium; obesity melatonin; breast cancer risk; antiestrogens; light-at-night; shift work; metalloestrogens; cadmium; obesity
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

González-González, A.; Mediavilla, M.D.; Sánchez-Barceló, E.J. Melatonin: A Molecule for Reducing Breast Cancer Risk. Molecules 2018, 23, 336.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top